Physician profile
Namitha Bhat
NPI 1235410739
$3,197.56
in general payments reported to CMS, 2019-2025
23 companies · $70.14 in 2025
The $70.14 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $301 · 2021: $422 · 2022: $1,563 · 2023: $811 · 2024: $30.82 · 2025: $70.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.18 |
| Education | $193.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,137.23 | 2020-2025 | Ozempic |
| Lilly USA, LLC | $510.91 | 2021-2023 | Mounjaro |
| Amgen INC. | $262.01 | 2020-2022 | |
| Dexcom, INC. | $199.95 | 2022-2023 | Dexcom G7 Gss (161) |
| Xeris Pharmaceuticals, INC. | $175.05 | 2021-2022 | |
| Abbott Laboratories | $142.99 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Insulet Corporation | $122.91 | 2022-2023 | Omnipod |
| Abbvie INC. | $98.40 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $70.37 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.75 | 2022 | |
| Ibsa Pharma INC. | $58.44 | 2020-2021 | |
| Eusa Pharma (US) LLC | $53.13 | 2022 | |
| Recordati_rare_diseases_inc. | $53.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.51 | 2020-2022 | |
| Grt US Holding, INC. | $45.95 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $33.15 | 2022 | |
| Horizon Therapeutics Plc | $30.60 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $24.82 | 2022 | |
| Medtronic, INC. | $16.72 | 2021 | |
| Corcept Therapeutics | $16.11 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.55 | 2020 | |
| Amneal Pharmaceuticals LLC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Namitha Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.